<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of iron deficiency in patients on dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of iron deficiency in patients on dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of iron deficiency in patients on dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients on dialysis are often iron deficient due to gastrointestinal bleeding, blood drawing, operations, and the dialysis treatment itself. Patients on hemodialysis lose an average of 1 to 2 g of iron per year [<a href="#rid1">1</a>].</p><p>Adequate iron stores are essential for achieving optimal hemoglobin (Hb) levels and maximum benefit from erythropoiesis-stimulating agents (ESAs) or hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF PHIs). Decreased iron stores or decreased availability of iron are the most common reasons for resistance to the effect of these agents.</p><p>This topic reviews surveillance for iron deficiency, the indications for iron therapy, and options for treatment of iron deficiency among patients on dialysis. The evaluation and management of anemia among patients with dialysis and nondialysis chronic kidney disease is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1943.html" rel="external">"Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1935.html" rel="external">"Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease"</a>.)</p><p></p><p class="headingAnchor" id="H2935613859"><span class="h1">DIAGNOSIS OF IRON DEFICIENCY</span><span class="headingEndMark"> — </span>Among all individuals, the gold standard for the diagnosis of iron deficiency is a bone marrow biopsy that shows a lack of stainable iron in erythroid precursors and marrow macrophages (see  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'</a>). However, bone marrow biopsies to assess iron stores are rarely done in patients on dialysis. Instead, iron stores are estimated in such patients. Estimation methods include measurement of the serum iron, total iron-binding capacity (TIBC), and ferritin and calculation of the percent transferrin saturation (TSAT); determination of the percentage of hypochromic red blood cells (RBCs); and determination of the reticulocyte hemoglobin (Hb) content. (See  <a class="medical medical_review" href="/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease"</a>.)</p><p>We use the serum iron, TIBC, and ferritin and calculation of the percent TSAT to estimate iron stores. Other methods may be more extensively used in Europe but are not widely available in the United States. (See  <a class="medical medical_review" href="/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease", section on 'Percent hypochromic HRCs and reticulocyte hemoglobin content'</a>.)</p><p>The laboratory criteria that are used to define iron deficiency and provide indication for treatment are markedly different among chronic kidney disease (CKD) patients compared with patients with relatively normal kidney function. Laboratory criteria for the diagnosis of absolute and functional iron deficiency in dialysis and nondialysis CKD patients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H1162817457"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>All patients should be surveilled for anemia when they start dialysis, particularly if they have not been closely followed prior to initiation of dialysis. Patients who are anemic should be surveilled for iron deficiency. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Surveillance'</a>.) </p><p>After the initial evaluation, we continue to routinely monitor all patients on dialysis for anemia and iron deficiency. Both are common among patients on dialysis; iron deficiency is a particular concern among patients on hemodialysis because of blood loss associated with the dialysis treatment and associated lab tests. Surveillance tests for iron deficiency include the percent transferrin saturation (TSAT), which is the plasma iron divided by total iron-binding capacity (TIBC) x 100, and the serum ferritin concentration. The frequency of surveillance is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Continued monitoring'</a>.)</p><p class="headingAnchor" id="H1452286536"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H4"><span class="h2">Indications</span><span class="headingEndMark"> — </span>The indications for treatment with iron vary depending upon the hemoglobin (Hb) level, whether the patient is also on erythropoiesis-stimulating agents (ESAs), and the likelihood of benefit from attaining and maintaining a higher Hb level. A detailed discussion of specific indications is presented at length elsewhere. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Indications for treatment'</a>.)</p><p class="headingAnchor" id="H3151854579"><span class="h2">Dosing and administration</span></p><p class="headingAnchor" id="H954605239"><span class="h3">Loading dose iron</span><span class="headingEndMark"> — </span>We give a loading dose of iron among patients who meet indications for treatment of iron deficiency anemia as discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Indications for treatment'</a>.)</p><p>Patients with symptoms of an underlying infection should undergo appropriate evaluation and treatment prior to treatment with iron.</p><p>We do not prescribe oral iron for treatment of iron deficiency in patients on dialysis. Our preferred regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span>125 mg of sodium <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> complex in sucrose given at each consecutive hemodialysis treatment for a total of eight doses (1000 mg in total) [<a href="#rid2">2-7</a>]. In patients on peritoneal dialysis, three to four doses are given weekly or less frequently (eg, monthly at dialysis clinic visits) for patient convenience.</p><p></p><p><strong>OR</strong></p><p class="bulletIndent1"><span class="glyph">●</span>100 mg <a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">iron sucrose</a> given at each consecutive hemodialysis treatment for a total of 10 doses (1000 mg in total) [<a href="#rid8">8-14</a>]. In patients on peritoneal dialysis, five doses are typically given (often monthly for patient convenience).</p><p></p><p><strong>OR</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9044" href="/d/drug information/9044.html" rel="external">Ferumoxytol</a> 510 mg given at the end of two hemodialysis sessions one to four weeks apart [<a href="#rid15">15-19</a>]. Dosing is similar in patients receiving peritoneal dialysis.</p><p></p><p>In the United States, approximately 90 percent of patients receive <a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">iron sucrose</a>, and most of the remaining patients receive sodium <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> [<a href="#rid20">20</a>].</p><p>Our goal with any loading regimen is to increase Hb levels and raise the transferrin saturation (TSAT). However, if the patient continues to meet criteria for iron deficiency anemia based on repeat testing of TSAT and serum ferritin at least two to three weeks after the last intravenous (IV) dose, then we give another 500 to 1000 mg of iron. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Indications for treatment'</a>.)</p><p>All IV iron preparations have the potential to be associated with acute reactions, including abdominal pain, nausea, chest pain, shortness of breath, flushing, pruritus, rash, hypotension, and anaphylactic-like reactions. The prevention and management of such reactions is discussed at length elsewhere. (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Allergic and infusion reactions'</a>.)</p><p>The approach of administering loading iron in the IV form (rather than oral) is consistent with the 2012 KDIGO guidelines and National Institute for Health and Care Excellence (NICE) guidelines [<a href="#rid21">21,22</a>]. Among patients on maintenance dialysis, compared with oral iron, IV iron is more effective for increasing Hb concentrations and iron stores [<a href="#rid23">23-27</a>]. The best data are from a meta-analysis of three trials including 300 patients on dialysis, which showed more patients achieved an Hb increase &gt;1 g/dL with IV compared with oral iron (risk ratio [RR] 2.14, 95% CI 1.68-2.72) [<a href="#rid27">27</a>]. If patients are also being treated with an ESA, then 1 g of IV iron is expected to raise the Hb from approximately 8 g/dL to 11 to 12 g/dL [<a href="#rid28">28</a>]. </p><p>Other less commonly used IV iron preparations include <a class="drug drug_general" data-topicid="90237" href="/d/drug information/90237.html" rel="external">ferric carboxymaltose</a> [<a href="#rid29">29-32</a>], <a class="drug drug_general" data-topicid="120585" href="/d/drug information/120585.html" rel="external">ferric derisomaltose</a> (formerly known as iron isomaltoside) [<a href="#rid33">33</a>], <a class="drug drug_general" data-topicid="99572" href="/d/drug information/99572.html" rel="external">ferric pyrophosphate citrate</a> [<a href="#rid34">34</a>], and low-molecular-weight <a class="drug drug_general" data-topicid="8574" href="/d/drug information/8574.html" rel="external">iron dextran</a>. In the United States, ferric carboxymaltose and ferric derisomaltose are not approved for use in patients on dialysis. However, in other countries, ferric derisomaltose is approved for use among patients receiving dialysis.</p><p>We do not use low-molecular-weight <a class="drug drug_general" data-topicid="8574" href="/d/drug information/8574.html" rel="external">iron dextran</a> unless it is the only IV iron preparation available because of the associated risk of adverse events (primarily anaphylaxis) [<a href="#rid35">35</a>]. The risk of anaphylaxis with the low-molecular-weight formulation, which is the only available preparation, is not likely appreciably different from other IV iron formulations. Nonetheless, because of this risk, iron dextran should be administered after an initial test dose of 25 mg. It is not necessary to premedicate patients prior to the test dose, but emergency medications (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, and corticosteroids) must be readily available. Anaphylaxis may still occur when the full dose is given, despite minimal or no reactions to the test dose [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H981117430"><span class="h3">Maintenance dose iron</span><span class="headingEndMark"> — </span>To ensure an adequate response with ESAs, most patients on dialysis require supplemental iron on a continuing basis for effective erythropoiesis. We give a maintenance dose of iron among patients who are deemed likely to benefit from supplemental iron while on an ESA. The indications for iron and ESAs in patients on dialysis is presented separately. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Indications for treatment'</a>.)</p><p>We prefer the following IV iron regimens for maintenance:</p><p class="bulletIndent1"><span class="glyph">●</span>Sodium <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> complex in sucrose at a dose of 125 mg administered once weekly or every other week </p><p></p><p><strong>OR</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">Iron sucrose</a> at a dose of 100 mg administered once weekly or every other week  </p><p></p><p>As noted above, IV iron has been shown to be more effective than oral iron [<a href="#rid23">23-27</a>]. Thus, among patients on hemodialysis, as with the loading dose of iron, we administer maintenance iron therapy parenterally rather than orally. </p><p>Similarly, among patients on peritoneal dialysis, we give IV rather than oral iron. An exception may be among patients who have limited IV access and who require preservation of sites for hemodialysis access; among such patients, we try oral iron first. Oral iron in patients with CKD is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1943.html" rel="external">"Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)", section on 'Oral iron'</a> and  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Oral iron'</a>.) </p><p>In addition, we identify and treat any underlying infections, if indicated, prior to treatment with iron. (See <a class="local">'Loading dose iron'</a> above.)</p><p>Once the desired Hb level is achieved, approximately 250 to 500 mg of iron may be required every three months to maintain adequate iron stores for support of erythropoiesis with ESA therapy.</p><p>Several well-designed trials have demonstrated that patients require a lower ESA dose and maintain a higher Hb when maintenance iron therapy is given [<a href="#rid37">37-40</a>]. The efficacy and safety of maintenance iron was evaluated in a noninferiority trial of 2141 patients on hemodialysis [<a href="#rid37">37</a>]. At the beginning of the trial, all patients were receiving ESA therapy and had a serum ferritin of &lt;400 ng/mL and TSAT &lt;30 percent. Patients were randomly assigned to receive high-dose IV <a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">iron sucrose</a> administered proactively (400 mg monthly, unless the serum ferritin level was &gt;700 ng/mL or TSAT was ≥40 percent) or low-dose iron sucrose administered reactively (0 to 400 mg monthly, given if serum ferritin was &lt;200 ng/mL or TSAT was &lt;20 percent). The median monthly dose of IV iron was 264 mg in the high-dose, proactive group and 145 mg in the low-dose, reactive group. At a median follow-up of 2.1 years, there was no difference between the groups in the composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death. However, patients in the high-dose, proactive treatment group required lower ESA doses (median monthly dose 29,757 versus 38,805 units) and were less likely to receive blood transfusions than those in the low-dose, reactive group. Rates of adverse events, including infection, were comparable between the two groups [<a href="#rid37">37,41</a>].</p><p class="headingAnchor" id="H8339863"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects that have been reported with IV iron include allergic reactions (including anaphylaxis) and nonallergic infusion reactions such as self-limiting urticaria, palpitations, dizziness, and neck and back spasm and an increased risk of bacterial infection and cardiovascular events. (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Allergic and infusion reactions'</a>.)</p><p>The risk of anaphylaxis varies with individual agents. The risk is highest with <a class="drug drug_general" data-topicid="8574" href="/d/drug information/8574.html" rel="external">iron dextran</a> and generally lower with newer agents such as sodium <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> complex in sucrose, <a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">iron sucrose</a>, and <a class="drug drug_general" data-topicid="9044" href="/d/drug information/9044.html" rel="external">ferumoxytol</a> but is very low with all available preparations. </p><p>Some studies have reported increased mortality and infection risk related to high doses of IV iron [<a href="#rid42">42-44</a>]. However, in a 2018 meta-analysis of trials and observational studies of over 241,000 patients on dialysis, compared with low-dose iron (either oral or IV), there was no increased risk of adverse events with high-dose IV iron (defined as &gt;400 mg per month) [<a href="#rid45">45</a>]. Specifically, there was no increased risk of mortality in the analysis of the trial data (403 patients, RR 0.93, 95% CI 0.47-1.84) or observational studies (241,408 patients, RR 1.09, 95% CI 0.98-1.21). Additionally, there was no increased risk of infections, cardiovascular events, or hospitalizations with high-dose IV iron. However, the relatively small number of events and participants in the included trials and the presence of significant heterogeneity in the included observational studies were limitations that reduce the certainty around these findings. In addition, the included trials used several different iron formulations and were performed over a period of time when guidelines regarding the target Hb concentration and iron dosing practices were evolving, likely contributing to some of the heterogeneity [<a href="#rid46">46</a>]. </p><p class="headingAnchor" id="H550051800"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111938.html" rel="external">"Society guideline links: Anemia in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Adequate iron stores are essential for achieving maximum benefit from erythropoiesis-stimulating agents (ESAs) or hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF PHIs). Decreased iron stores or decreased availability of iron are the most common reasons for resistance to the effect of these agents. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of iron deficiency</strong> – We use the serum iron, total iron-binding capacity (TIBC), and ferritin and calculation of the percent transferrin saturation (TSAT) to identify iron deficiency. (See <a class="local">'Diagnosis of iron deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment</strong> – The indications for iron treatment are discussed at length separately. (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Indications for treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration of iron therapy</strong> – Among patients on dialysis selected for iron therapy, we recommend parenteral rather than oral iron therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In this population, intravenous (IV) iron is more effective compared with oral iron for increasing hemoglobin (Hb) concentrations and iron stores. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Loading dose</strong> – Among patients who need a loading dose of iron, we prefer one of the following regimens (see <a class="local">'Loading dose iron'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Sodium <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> complex in sucrose at a dose of 125 mg given at each consecutive hemodialysis session for a total of eight doses; in patients on peritoneal dialysis, three to four doses are given weekly or less frequently (eg, monthly) for patient convenience. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">Iron sucrose</a> at a dose of 100 mg given at each consecutive hemodialysis session for a total of 10 doses; in patients on peritoneal dialysis, five doses are given (often monthly for patient convenience).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9044" href="/d/drug information/9044.html" rel="external">Ferumoxytol</a> at a dose of 510 mg given at the end of two hemodialysis sessions one to four weeks apart; dosing is similar in patients receiving peritoneal dialysis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance dose</strong> – Among patients who need maintenance dose of iron (eg, patients on an ESA), we prefer one of the following regimens (see <a class="local">'Maintenance dose iron'</a> above): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Sodium <a class="drug drug_general" data-topicid="8936" href="/d/drug information/8936.html" rel="external">ferric gluconate</a> complex in sucrose at a dose of 125 mg administered once weekly or every other week. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9004" href="/d/drug information/9004.html" rel="external">Iron sucrose</a> at a dose of 100 mg administered once weekly or every other week. </p><p></p><p class="bulletIndent2">Oral iron is sometimes used in patients receiving peritoneal dialysis who have limited IV access and who require preservation of sites for hemodialysis access. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects that have been reported with IV iron include allergic reactions (including anaphylaxis) and nonallergic infusion reactions such as self-limiting urticaria, palpitations, dizziness, and neck and back spasm and an increased risk of bacterial infection and cardiovascular events. (See <a class="local">'Adverse effects'</a> above and  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Allergic and infusion reactions'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87:710.</a></li><li><a class="nounderline abstract_t">Nissenson AR, Lindsay RM, Swan S, et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999; 33:471.</a></li><li><a class="nounderline abstract_t">Matzke GR. Intravenous iron supplementation in end-stage renal disease patients. Am J Kidney Dis 1999; 33:595.</a></li><li><a class="nounderline abstract_t">Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 2001; 37:879.</a></li><li><a class="nounderline abstract_t">Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or =250 mg) administration. Am J Kidney Dis 2003; 41:651.</a></li><li><a class="nounderline abstract_t">Canavese C, Bergamo D, Ciccone G, et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 2004; 19:1564.</a></li><li><a class="nounderline abstract_t">Michael B, Coyne DW, Folkert VW, et al. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant 2004; 19:1576.</a></li><li><a class="nounderline abstract_t">Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66:1193.</a></li><li><a class="nounderline abstract_t">Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41:18.</a></li><li><a class="nounderline abstract_t">Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20:1443.</a></li><li><a class="nounderline abstract_t">Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72:413.</a></li><li><a class="nounderline abstract_t">Charytan C, Levin N, Al-Saloum M, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37:300.</a></li><li><a class="nounderline abstract_t">Sheashaa H, El-Husseini A, Sabry A, et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. Nephron Clin Pract 2005; 99:c97.</a></li><li><a class="nounderline abstract_t">Schiesser D, Binet I, Tsinalis D, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006; 21:2841.</a></li><li><a class="nounderline abstract_t">Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25:400.</a></li><li><a class="nounderline abstract_t">Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68:1801.</a></li><li><a class="nounderline abstract_t">Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19:1599.</a></li><li><a class="nounderline abstract_t">Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:386.</a></li><li><a class="nounderline abstract_t">Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014; 9:705.</a></li><li class="breakAll">https://www.dopps.org/DPM-HD/DPMSlideBrowser.aspx?type=Topic&amp;id=1 (Accessed on November 01, 2021).</li><li><a class="nounderline abstract_t">Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011) 2012; 2:288.</a></li><li class="breakAll">https://www.nice.org.uk/guidance/ng8/resources/chronic-kidney-disease-managing-anaemia-51046844101 (Accessed on May 26, 2016).</li><li><a class="nounderline abstract_t">Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694.</a></li><li><a class="nounderline abstract_t">Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79:299.</a></li><li><a class="nounderline abstract_t">Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25:433.</a></li><li><a class="nounderline abstract_t">Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012; 1:CD007857.</a></li><li><a class="nounderline abstract_t">Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68:677.</a></li><li><a class="nounderline abstract_t">KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47:S11.</a></li><li><a class="nounderline abstract_t">Bielesz B, Lorenz M, Monteforte R, et al. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Clin J Am Soc Nephrol 2021; 16:1512.</a></li><li><a class="nounderline abstract_t">Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009; 71:125.</a></li><li><a class="nounderline abstract_t">Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2014; 29:833.</a></li><li><a class="nounderline abstract_t">Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29:2075.</a></li><li><a class="nounderline abstract_t">Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31:646.</a></li><li><a class="nounderline abstract_t">Fishbane S, Shah HH. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis. Hemodial Int 2017; 21 Suppl 1:S104.</a></li><li><a class="nounderline abstract_t">Wang C, Graham DJ, Kane RC, et al. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA 2015; 314:2062.</a></li><li><a class="nounderline abstract_t">Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743.</a></li><li><a class="nounderline abstract_t">Macdougall IC, White C, Anker SD, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med 2019; 380:447.</a></li><li><a class="nounderline abstract_t">Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34:21.</a></li><li><a class="nounderline abstract_t">Bolaños L, Castro P, Falcón TG, et al. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 2002; 22:67.</a></li><li><a class="nounderline abstract_t">Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15:1623.</a></li><li><a class="nounderline abstract_t">Macdougall IC, Bhandari S, White C, et al. Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. J Am Soc Nephrol 2020; 31:1118.</a></li><li><a class="nounderline abstract_t">Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87:162.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3070.</a></li><li><a class="nounderline abstract_t">Miskulin DC, Tangri N, Bandeen-Roche K, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014; 9:1930.</a></li><li><a class="nounderline abstract_t">Hougen I, Collister D, Bourrier M, et al. Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2018; 13:457.</a></li><li><a class="nounderline abstract_t">Li X, Kshirsagar AV. Rest Easy with Intravenous Iron for Dialysis Patients? High Dose IV Iron Safety. Clin J Am Soc Nephrol 2018; 13:363.</a></li></ol></div><div id="topicVersionRevision">Topic 1953 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/931207" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Iron balance in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070911" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10070926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intravenous iron supplementation in end-stage renal disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325667" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612989" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt;or =250 mg) administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004263" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034152" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327417" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12776310" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety in iron management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855210" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hypersensitivity reactions and deaths associated with intravenous iron preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852489" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intravenous ferric saccharate as an iron supplement in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157370" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692217" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891647" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088081" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164657" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525001" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ferumoxytol for treating iron deficiency anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19176796" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458078" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458078" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chapter 1: Diagnosis and evaluation of anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chapter 1: Diagnosis and evaluation of anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914038" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized controlled study of iron supplementation in patients treated with erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9678430" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872321" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258974" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Parenteral versus oral iron therapy for adults and children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27321965" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678659" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34470831" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203504" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963731" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891437" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250435" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371161" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575062" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11273874" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Suspected iron dextran-related adverse drug events in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30365356" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401011" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A study of parenteral iron regimens in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919405" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153574" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Administration of parenteral iron and mortality among hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32253271" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075769" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033854" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Time-dependent associations between iron and mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25318751" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravenous iron exposure and mortality in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463597" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463596" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rest Easy with Intravenous Iron for Dialysis Patients? High Dose IV Iron Safety.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
